Welcome to our dedicated page for Arcturus Therape news (Ticker: ARCT), a resource for investors and traders seeking the latest updates and insights on Arcturus Therape stock.
Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) is a San Diego-based commercial mRNA medicines and vaccines company focused on liver and respiratory rare disease therapeutics and infectious disease vaccines. News about Arcturus often centers on clinical trial progress, regulatory interactions and collaboration updates linked to its LUNAR® lipid-mediated delivery and STARR® self-amplifying mRNA (sa-mRNA) platforms.
Investors following ARCT news can expect regular updates on the companys RNA therapeutic candidates for ornithine transcarbamylase (OTC) deficiency and cystic fibrosis (CF), including interim data from Phase 1 and Phase 2 studies, safety and tolerability findings, biomarker changes and plans for longer-duration or pivotal trials. Disclosures have highlighted programs such as ARCT-032, an inhaled mRNA therapy for CF, and ARCT-810, an mRNA therapeutic candidate for OTC deficiency.
Arcturus also issues frequent announcements related to its infectious disease vaccine portfolio. These include developments for KOSTAIVE®, described as the first approved self-amplifying mRNA COVID-19 vaccine, along with sa-mRNA influenza candidates like ARCT-2138 and pandemic influenza A H5N1 candidate ARCT-2304. News items may cover Phase 1 or Phase 3 data, immunogenicity and safety results, and regulatory submissions or approvals in collaboration with CSL Seqirus and partners such as Meiji Seika Pharma.
Additional ARCT headlines often involve financial results, cash runway commentary, cost management actions, investor conference participation and SEC filings that provide corporate updates. Stock Titans ARCT news page aggregates these company press releases, regulatory disclosures and related coverage so readers can track how Arcturus clinical, regulatory and partnership milestones may influence sentiment around ARCT stock over time.
Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) announced the grant of stock options for 11,200 shares to three new employees as part of their employment compensation. The options, priced at $24.85 per share, are granted under the Nasdaq Rule 5635(c)(4) inducement exception. These stock options will vest over four years, with 25% vesting after one year and the rest monthly over the subsequent three years, contingent on continued employment. This move supports Arcturus's commitment to attract top talent in the competitive biotech landscape.
Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) will announce its financial results for the quarter and year ended December 31, 2021, after market close on February 28, 2022. A conference call and webcast will follow at 4:30 PM EST on the same day. The company specializes in developing mRNA medicines, focusing on vaccines for infectious diseases and rare liver and respiratory diseases. Arcturus leverages unique technologies, including LUNAR® lipid-mediated delivery and STARR™ mRNA Technology, in its diverse pipeline targeting various conditions including COVID-19 and cystic fibrosis.
Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) announced its participation in the SVB Leerink 11th Annual Global Healthcare Conference on February 18, 2022, at 12:00 PM ET. Management team members, including CEO Joseph Payne and CFO Andrew Sassine, will present a corporate overview followed by a Q&A session. Investors can register for the presentation here. A replay will be available on Arcturus’ Investor Relations website for 90 days post-event.
Arcturus Therapeutics (NASDAQ: ARCT) announced promising findings from its Phase 1/2 booster trial for mRNA vaccine candidates ARCT-154 and ARCT-165. The study demonstrated 54-fold and 47-fold increases in neutralizing antibody titers against the Omicron variant after administering low doses (5 mcg) at least five months post-initial vaccination. This data supports expanding clinical development aimed at evaluating the candidates as effective COVID-19 booster vaccines. The ongoing trial is being conducted in the U.S. and Singapore.
Arcturus Therapeutics announced positive results from its Phase 1/2 booster study of ARCT-154 and ARCT-165 vaccines. The data showed a significant 30-fold increase in neutralizing antibody concentrations against SARS-CoV-2 at Day 15, maintained at 28-fold by Day 29. Both vaccines demonstrated strong responses against various COVID-19 variants, supporting their potential as booster options. Administered as low-dose boosters, they were well-tolerated, indicating promise in ongoing clinical development.
Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) announced the approval of stock options totaling 5,800 shares to a new employee as part of their compensation package. The options have an exercise price of $27.21 per share, based on the closing price on January 18, 2022. They feature a ten-year term with a one-year vesting period for 25% of the shares, followed by monthly vesting over three years. This grant aligns with Nasdaq Rule 5635(c)(4) and is intended to encourage the new hire’s acceptance of employment.
Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) announced stock options grants totaling 13,800 shares to three new employees. The grants, approved by the Compensation Committee and Board, serve as an incentive for employment acceptance. The exercise price is set at $35.52, matching the closing stock price on December 15, 2021. The options vest over four years, starting with 25% after one year and the remainder monthly over the next three years, contingent on continued employment. Arcturus focuses on developing mRNA medicines and vaccines for various diseases.
Arcturus Therapeutics has reported preliminary findings from its ongoing clinical study of ARCT-154 and ARCT-165. The data reveals a significant 50-fold increase in neutralizing antibody levels against SARS-CoV-2 following a boost with ARCT-154. The vaccine candidates show activity against various variants and will be evaluated for effectiveness against the omicron variant, with initial data expected in Q1 2022. The Phase 1/2 trials are being conducted in the U.S. and Singapore, with regulatory submissions for ARCT-154 expected soon in Vietnam.
Arcturus Therapeutics (NASDAQ: ARCT) has announced the appointment of Dr. Jing Marantz, an accomplished biopharma executive, to its Board of Directors. Dr. Marantz brings extensive clinical expertise and industry experience, having held senior positions at prominent biopharma companies such as Acceleron and Alnylam Pharmaceuticals. CEO Joseph Payne expressed confidence in Dr. Marantz's ability to contribute to the advancement of Arcturus's vaccine programs, including those targeting COVID-19 and other mRNA-based therapeutic candidates.
Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) will participate in the Piper Sandler’s 33rd Annual Virtual Healthcare Conference from November 30 to December 02, 2021. A pre-recorded fireside chat will be available on-demand starting November 22, 2021, at 10:00 a.m. ET. Founded in 2013 and based in San Diego, Arcturus specializes in mRNA medicines and vaccines, with a pipeline that includes candidates for COVID-19, influenza, and various rare diseases. The company utilizes advanced technologies like LUNAR® and STARR™ to develop innovative therapies.